1.Comparison of the Toxicities and Efficacies of the Combination Chemotherapy Regimens in Advanced Gastric Cancer Patients Who Achieved Complete Response after Chemotherapy.
Yun Jeung KIM ; Pyung Gohn GOH ; Eui Sik KIM ; Su Youn LEE ; Hee Seok MOON ; Eaum Seok LEE ; Jae Kyu SUNG ; Seok Hyun KIM ; Byung Seok LEE ; Hyun Yong JEONG
The Korean Journal of Gastroenterology 2011;58(6):311-317
BACKGROUND/AIMS: We retrospectively analyzed comparative toxicities and efficacies of chemotherapy regimens in advanced gastric cancer (AGC) patients who achieved complete response (CR) after chemotherapy. METHODS: We reviewed the medical records of 1,203 patients, who were pathologically diagnosed as AGC in a single center between January 2001 and October 2007. On the basis of the Response Evaluation Criteria in Solid Tumors, CR was evaluated with abdominal computed tomography. Toxicities were evaluated using the National Cancer Institute's common toxicity criteria before each chemotherapy cycle. RESULTS: Among the 1,203 AGC patients enrolled in this study, 568 received chemotherapy and 635 received best supportive care. The major chemotherapy regimens were 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX), docetaxel, cisplatin and 5-fluorouracil (DCF) and 5-fluorouracil, leucovorin and irinotecan (FOLFIRI). Among the 568 patients, 51 (9.0%) achieved CR (49 [8.6%] with FOLFOX [n=12], DCF [n=26], or FOLFIRI [n=11] and 2 [0.3%] with etoposide, leucovorin and 5-fluorouracil). For patients administered FOLFOX, DCF, and FOLFIRI, the median time to disease progression was 4 months (range, 1.8-59.5), 15 months (range, 2.9-31.2) and 10 months (range, 2.0-39.5), and the median survival times were 48 months (range, 5.9-74.0), 37 months (range, 14.0-86.0), and 30 months (range, 6.0-50.0), respectively. Grades 3-4 mucositis occurred mostly in patients administered DCF (n=8, 30.8%). Grades 3-4 leucopenia were observed in 1 (8.3%), 11 (42.3%), and 4 (36.4%) patients administered FOLFOX, DCF and FOLFIRI, respectively. No statistically significant differences were observed in the 3 regimens. CONCLUSIONS: All 3 regimens (FOLFOX, DCF and FOLFIRI) were active and tolerable. Their efficacies and toxicities were not significantly different.
Adult
;
Aged
;
Antineoplastic Agents/*therapeutic use/toxicity
;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use/toxicity
;
Camptothecin/analogs & derivatives/therapeutic use/toxicity
;
Cisplatin/therapeutic use/toxicity
;
Drug Therapy, Combination
;
Female
;
Fluorouracil/therapeutic use/toxicity
;
Humans
;
Leucovorin/therapeutic use/toxicity
;
Leukopenia/etiology
;
Male
;
Middle Aged
;
Mucositis/etiology
;
Nausea/etiology
;
Neoplasm Staging
;
Organoplatinum Compounds/therapeutic use/toxicity
;
Retrospective Studies
;
Stomach Neoplasms/*drug therapy/mortality
;
Survival Rate
;
Taxoids/therapeutic use/toxicity
;
Tomography, X-Ray Computed
;
Vomiting/etiology
2.Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane.
Jin Hee AHN ; Sung Bae KIM ; Tae Won KIM ; Sei Hyun AHN ; Sun Mi KIM ; Jeong Mi PARK ; Jung Shin LEE ; Yoon Koo KANG ; Woo Kun KIM
Journal of Korean Medical Science 2004;19(4):547-553
We have evaluated the efficacy and safety of the combination of capecitabine and vinorelbine in metastatic breast cancer (MBC) patients previously treated with anthracycline-and taxane-containing regimens. Between April 2000 and September 2002, 44 female MBC patients received oral capecitabine (1,250 mg/m(2) twice daily on days 114), and intravenous vinorelbine (25 mg/m2 on days 1 and 8) during each 3 weekchemotherapy cycle (median, 5 cycles/patient; total, 235 cycles). One patient achieved a complete response and 21 patients had partial responses, giving an overall response rate of 50% in the intention-to-treat analysis (95% CI, 35.0-65.0%). Median duration of response was 6.0 months (range 1.2-23.0 months). Patients were followed- up for a median of 16 months, with median progression-free survival being 5.3 months, and median overall survival being 17 months. Toxicities included grades III and IV neutropenia in 63 (26.8%) and 4 (1.7%) cycles, respectively, and grades II and III hand-foot syndrome in 12 (5.1%) and 4 (1.7%) cycles, respectively. Other nonhematologic toxicities were minimal and manageable. In conclusion, the combination of capecitabine and vinorelbine was effective and well tolerated in MBC patients even after treatment with anthracyclines and taxanes.
Adult
;
Aged
;
Anthracyclines/*therapeutic use
;
Antineoplastic Agents/*therapeutic use/toxicity
;
Breast Neoplasms/*drug therapy/*pathology
;
Deoxycytidine/*analogs & derivatives/*therapeutic use/toxicity
;
Drug Therapy, Combination
;
Female
;
Humans
;
Middle Aged
;
Neoplasm Metastasis
;
Prodrugs
;
Retrospective Studies
;
Survival Rate
;
Taxoids/*therapeutic use
;
Treatment Outcome
;
Vinblastine/*analogs & derivatives/*therapeutic use/toxicity